CD70 标靶治疗的全球市场：市场机会与临床试验见解（2024 年）

在癌症治疗的动态格局中，精准医学的出现正在彻底改变治疗模式，提供利用个别肿瘤独特模式的客製化方法。 近年来，生物技术和製药公司各利益相关者的好奇心因参与肿瘤发生和进展的关键分子启动子的鑑定而凸显，从一刀切的模型转向定制的一刀切的模型。引起人们的注意。 其中，CD70蛋白已成为一个有前景的治疗标靶，在癌症治疗和其他治疗领域具有巨大潜力。

将 CD70 作为治疗标靶的研究正在扩大癌症患者更有效、个人化和客製化治疗选择的范围。 最初，CD70 蛋白参与 T 细胞和 B 细胞的活化。 然而，临床前研究证据显示 CD70 蛋白会触发磷脂□肌醇 3 激□ (PI3K) 和 MAP 激□讯号路径的活化。 此讯号通路的活化进一步导致众多转录因子的激活，从而触发与细胞增殖和存活相关的基因的表达，从而导致癌症疾病。

透过临床前研究提供研究证据有助于增强世界各地各利害关係人之间的信任和好奇心。 因此，许多製药和生物技术公司计划开发CD70疗法并已开始临床试验。 推动 CD70 蛋白治疗市场的关键驱动力之一是进行新颖研究的研究合作数量不断增加。 许多公司正在与研究机构和医院合作，以推进 CD70 治疗市场。 例如，重庆精准生物科技与国内南昌大学第一附属医院、浙江大学、山西白求恩医院等科研院所和医院合作，进行剩余的CD70临床前和临床研究。

Cusatuzumab (ARGX-110) 是目前最先进的 CD70 候选药物，作为白血病治疗已达到 II 期临床阶段。 除了抗CD70抗体之外，许多其他治疗方法，例如CAR-T细胞疗法、CAR-NK疗法和针对CD70蛋白的4特异性抗体，代表了CD70疗法的不断发展的领域。 此外，随着CD70蛋白研究的进一步进展，该领域前景广阔，前景广阔。

本报告检视了全球 CD70 标靶治疗市场，并提供了市场概况，包括药物趋势、临床试验趋势、区域趋势以及进入市场的公司竞争格局。

目录

第1章揭示 CD70 标靶治疗的复杂性

• CD70标靶治疗概述
• CD70标靶治疗的历史与发展
• CD70 标靶治疗的先决条件
• CD70 作为诊断和预后生物标记的双重作用

第 2 章 CD70 标靶治疗的临床方法

• 单株抗体
• 双特异性抗体
• 四特异性抗体
• CAR T 细胞疗法
• 抗体药物偶联物
• CAR-NK疗法

第3章 CD70标靶治疗的联合策略

• 与免疫疗法结合
• 与表观遗传调节剂组合
• 与标靶治疗结合
• 与溶瘤病毒疗法合併使用
• 与化疗合併使用

第 4 章 CD70 标靶治疗：当前临床发展趋势与创新（按适应症）

• 白血病
• 淋巴瘤
• 妇科癌症
• 肾细胞癌
• 肺癌
• 自体免疫疾病与发炎性疾病
• 病毒感染

第5章全球CD70标靶治疗临床试验概述

• 爱别
• 依国家/地区
• 按公司
• 依指示
• 依优先权
• 患者部分

第 6 章 CD70 标靶治疗候选药物获得 FDA 和 EMA 指定

第7章全球CD70标靶治疗的当前市场趋势与发展

• 当前市场概览
• 未来市场预测

第 8 章 CD70 标靶治疗市场机会与临床趋势（按地区）

• 美国
• 中国
• 欧洲

第 9 章公司与 CD70 标靶治疗开发平台（按技术）

第10章全球CD70标靶治疗市场动态

• 市场驱动因素
• 市场挑战

第11章全球CD70标靶治疗临床试验洞察

• 临床前
• 第一阶段
• 第一/二期
• 第二阶段

第12章竞争态势

• Acepodia
• Adaptimmune
• Adicet Bio
• Allogene Therapeutics
• Ambrx (Johnson & Johnson)
• Chinook Therapeutics (Novartis)
• CRISPR Therapeutics
• ImmuneOnco Biopharma
• Pfizer
• Poseida Therapeutics

Global CD70 Targeting Therapies Market Opportunity & Clinical Trials Insight 2024 Report Highlights:

• CD70 Targeting Therapies In Clinical Trials: > 20 Therapies
• CD 70 Targeting Therapies Clinical Trials Insight By Company, Country, Indication & Phase
• Insight On CD70 Targeting Therapy Technology Platforms: 6 Platforms
• FDA & EMA Designations Insight: Orphan, FTD, RMAT Designation
• Combination Stratagems for CD70 Targeting Therapies
• Insight On 10 Companies Involved In Development Of CD70 Therapies

In the dynamic landscape of cancer therapeutics, the emergence of precision medicine has transformed treatment paradigms, offering tailored approaches that take advantage of the unique patterns of individual tumors. Recently, the curiosity of various stakeholders from the biotech and pharma companies have turned the limelight from a one size fits all model to a tailored therapeutic strategy that has been underscored by the identification of key molecular drivers implicated in tumorigenesis and progression. Among these, CD70 protein has emerged as a promising therapeutic target, clenching immense potential in the realm of cancer therapy and other treatments.

The research of CD70 as a therapeutic target clenches the panorama of more effective, personalized and customized therapy choices for cancer patients. Initially, the CD70 protein was involved in T cell and B cell activation. However, augmenting evidences from preclinical studies signifies that CD70 protein causes activation of the phosphatidylinositol-3 kinase (PI3K) together with MAP kinase signaling pathways. This activation of signaling pathways further results in activation of numerous transcription factors and thereby the expression of genes involved in cell growth along with survival and causing cancer diseases.

Bestowing research evidences from preclinical studies aid to build confidence and inquisitiveness among various stakeholders across the globe. Therefore, numerous pharma and biotech companies planned to develop CD70 therapy and initiated clinical trials. One of the significant prime movers that aid to advance CD70 protein therapy market is the rise in research collaborations to conduct novel studies. Many firms are joining hands with research institute and hospitals to headway CD70 therapy market. For instance, Chongqing Precision Biotech has partnership with institutes and hospitals, including The First Affiliated Hospital of Nanchang University, Zhejiang University or Shanxi Bethune Hospital etc., in China to conduct surplus CD70 preclinical and clinical studies.

Concurrently, in the pharmaceutical sector, CD70 targeted therapeutic intervention characterize a promising revolution area. Over the preceding decennium, the sphere of global CD70 therapy market has witnessed the development of several novel, innovative as well as advanced contenders targeting CD70. For instance, candidates like SGN-CD70, bi-4SCAR GD2/ CD70 T cells, CD70 CAR-T cells, CB dualCAR- NK19/70, CTX130, CTX131, ALLO-316 and others have been developed by in the preceding years for the treatment of cancer ailments. As research and advancement expands, it is anticipated that numerous other innovative CD70 therapy will be perceived in future.

Moreover, in order to further augment the therapeutic window in conjugation with boost efficacy, pharma companies have initiated the combinational study of CD70 therapy with other therapies. Currently, a handful of combinations of CD70 therapy are being invested with immunotherapies like CAR-T therapy combination or amalgamation of CAR-T with monoclonal antibody, targeted therapies, chemotherapy, epigenetic modulators, oncolytic viruses and others. The combinational study for CD70 therapy represents a novel as well as compelling frontier in the commercial CD70 therapy landscape.

Solitary of the key characteristics which aid to amplify the sphere of CD70 targeted therapy is fostering investments and collaborations. These partnerships and investments among academic institutions, smaller biotech firms, and larger pharmaceutical companies also aid to speed up the discovery and commercialization of CD70 therapy. For instance, in February 2024, ProfoundBio has raised an investment of US$ 112 Million in Series B financing round in order to advance in its preclinical programs, including PRO1160, a CD70 targeted antibody drug conjugate.

All these examples demonstrate that the realm of CD70 therapy is burgeoning at an incredible gait. At present, US dominates the CD70 therapy segment in terms of research and development. However, China is additionally up surging and expanding the CD70 therapy arena by developing innovative CD70 candidates coupled with initiating many clinical trials. The evolutions from one size fits all model to a tailored therapeutic strategy suggests that developing CD70 therapy clenches immense potential.

Currently, Cusatuzumab (ARGX-110) is the most advanced CD70 candidates that have reached phase II clinical stage for leukemia treatment. In addition to anti-CD70 antibodies, multitudinous other therapeutic approach like CAR-T cell therapy, CAR-NK therapy or tetraspecific antibodies targeting CD70 protein represents that the domain of CD70 therapy is evolving year by year. Moreover, as research further increases for CD70 protein, the domain represents a huge prospect and a fruitful future.

Table of Contents

1. Unlocking Intricacies for CD70 Targeting Therapy

• 1.1 Overview to CD70 Targeting Therapy
• 1.2 Chronicle & Development of CD70 Targeting Therapy
• 1.3 The Prerequisite for CD70 Targeting Therapy
• 1.4 Dual Role of CD70 As Diagnostic & Prognostic Biomarker

2. Clinical Approaches For CD70 Targeting Therapy

• 2.1 Monoclonal Antibody
• 2.2 Bispecific Antibody
• 2.3 Tetraspecific Antibody
• 2.4 CAR T Cell Therapy
• 2.5 Antibody Drug Conjugate
• 2.6 CAR-NK Therapy

3. Combination Stratagems for CD70 Targeting Therapies

• 3.1 In Combination with Immunotherapy
• 3.2 In Combination with Epigenetic Modulators
• 3.3 In Combination with Targeted Therapy
• 3.4 In Combination with Oncolytic Virus Therapy
• 3.5 In Combination with Chemotherapy

4. CD70 Targeting Therapy By Indications: Current Clinical Development Trends & Innovations

• 4.1 Leukemia
• 4.2 Lymphoma
• 4.3 Gynecologic Cancer
• 4.4 Renal Cell Carcinoma
• 4.5 Lung Cancer
• 4.6 Autoimmune & Inflammatory Disease
• 4.7 Viral Infections

5. Global CD 70 Targeting Therapy Clinical Trials Overview

• 5.1 By Phase
• 5.2 By Country
• 5.3 By Company
• 5.4 By Indication
• 5.5 By Priority Status
• 5.6 Patient Segment

6. CD70 Targeting Therapy Candidates Granted FDA & EMA Designations

7. Global CD70 Targeting Therapy Current Market Trend & Developments

• 7.1 Current Market Outline
• 7.2 Future Market Forecast

8. CD70 Targeting Market Opportunity & Clinical Trends by Region

• 8.1 US
• 8.2 China
• 8.3 Europe

9. CD70 Targeting Therapy Development Platforms By Company & Technology

• 9.1 AlloCAR T Platform
• 9.2 Gamma Delta Cell Platform
• 9.3 Tailwind Platform
• 9.4 DARPin Platform
• 9.5 SIMPLE antibody platform
• 9.6 Potelligent Technology

10. Global CD70 Targeting Therapy Market Dynamics

• 10.1 Market Drivers
• 10.2 Market Challenges

11. Global CD 70 Targeting Therapies Clinical Trials Insight

• 11.1 Preclinical
• 11.2 Phase I
• 11.3 Phase I/II
• 11.4 Phase II

12. Competitive Landscape

• 12.1 Acepodia
• 12.2 Adaptimmune (TCR2 Therapeutics )
• 12.3 Adicet Bio
• 12.4 Allogene Therapeutics
• 12.5 Ambrx (Johnson & Johnson)
• 12.6 Chinook Therapeutics (Novartis)
• 12.7 CRISPR Therapeutics
• 12.8 ImmuneOnco Biopharma
• 12.9 Pfizer
• 12.10 Poseida Therapeutics

List of Figures

1. Unlocking Intricacies for CD70 Targeting Therapy

• 1.1 Overview to CD70 Targeting Therapy
• 1.2 Chronicle & Development of CD70 Targeting Therapy
• 1.3 The Prerequisite for CD70 Targeting Therapy
• 1.4 Dual Role of CD70 As Diagnostic & Prognostic Biomarker

2. Clinical Approaches For CD70 Targeting Therapy

• 2.1 Monoclonal Antibody
• 2.2 Bispecific Antibody
• 2.3 Tetraspecific Antibody
• 2.4 CAR T Cell Therapy
• 2.5 Antibody Drug Conjugate
• 2.6 CAR-NK Therapy

3. Combination Stratagems for CD70 Targeting Therapies

• 3.1 In Combination with Immunotherapy
• 3.2 In Combination with Epigenetic Modulators
• 3.3 In Combination with Targeted Therapy
• 3.4 In Combination with Oncolytic Virus Therapy
• 3.5 In Combination with Chemotherapy

4. CD70 Targeting Therapy By Indications: Current Clinical Development Trends & Innovations

• 4.1 Leukemia
• 4.2 Lymphoma
• 4.3 Gynecologic Cancer
• 4.4 Renal Cell Carcinoma
• 4.5 Lung Cancer
• 4.6 Autoimmune & Inflammatory Disease
• 4.7 Viral Infections

5. Global CD 70 Targeting Therapy Clinical Trials Overview

• 5.1 By Phase
• 5.2 By Country
• 5.3 By Company
• 5.4 By Indication
• 5.5 By Priority Status
• 5.6 Patient Segment

6. CD70 Targeting Therapy Candidates Granted FDA & EMA Designations

7. Global CD70 Targeting Therapy Current Market Trend & Developments

• 7.1 Current Market Outline
• 7.2 Future Market Forecast

8. CD70 Targeting Market Opportunity & Clinical Trends by Region

• 8.1 US
• 8.2 China
• 8.3 Europe

9. CD70 Targeting Therapy Development Platforms By Company & Technology

• 9.1 AlloCAR T Platform
• 9.2 Gamma Delta Cell Platform
• 9.3 Tailwind Platform
• 9.4 DARPin Platform
• 9.5 SIMPLE antibody platform
• 9.6 Potelligent Technology

10. Global CD70 Targeting Therapy Market Dynamics

• 10.1 Market Drivers
• 10.2 Market Challenges

11. Global CD 70 Targeting Therapies Clinical Trials Insight

• 11.1 Preclinical
• 11.2 Phase I
• 11.3 Phase I/II
• 11.4 Phase II

12. Competitive Landscape

• 12.1 Acepodia
• 12.2 Adaptimmune (TCR2 Therapeutics )
• 12.3 Adicet Bio
• 12.4 Allogene Therapeutics
• 12.5 Ambrx (Johnson & Johnson)
• 12.6 Chinook Therapeutics (Novartis)
• 12.7 CRISPR Therapeutics
• 12.8 ImmuneOnco Biopharma
• 12.9 Pfizer
• 12.10 Poseida Therapeutics